Targets › FLT1
24 programs from 23 companies in 295 trials: 215 Phase 2, 40 Phase 1, 34 Phase 3, 6 Phase 4; Oncology, Other, Ophthalmology; next expected readout Dec 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression (By similarity). (UniProt, P17948)
Open in Phaseline: the race on FLT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 4 | Colorectal Cancer | Oct 2027 |
| Adverum Biotechnologies | Ixo-vec (ixoberogene soroparvovec) Intravitreal gene therapy expressing soluble fms-like tyrosine kinase-1 (sFlt-1), a VEGF t | FLT1 | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD); Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Dec 2026 |
| Shanghai Junshi Bioscience Co., Ltd. | Lenvatinib mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Advanced Hepatocellular Carcinoma (HCC); Intrahepatic Cholangiocarcinoma | Dec 2026 |
| Ocular Therapeutix | Axitinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Neovascular Age-related Macular Degeneration; Non-Proliferative Diabetic Retinopathy; Neovascular Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD) … | Jan 2027 |
| University Hospital, Bordeaux | PD-1/PD-L1 ICI + VEGFR-TKI combination PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor | PDCD1, CD274, KDR, FLT1, FLT4 | Phase 3 | Metastatic Renal Cell Carcinoma | Jan 2027 |
| Merck & Co. (MSD) | Lenvatinib (MK-7902) Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Carcinoma, Renal Cell; Solid Tumors; Neoplasm Malignant; Esophageal Squamous Cell Carcinoma … | Feb 2027 |
| Jiangsu HengRui Medicine | Famitinib Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | KIT, FLT1, FLT3, PDGFRB, PDGFRA | Phase 3 | Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm … | May 2027 |
| AO GENERIUM | GNR-139 Aflibercept biosimilar; VEGF-A and PlGF antagonist; binds VEGFR1 and VEGFR2 | FLT1, KDR, FLT4 | Phase 3 | nAMD | May 2028 |
| Hutchmed | fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Advanced Endometrial Cancer; Advanced Renal Cell Carcinoma | Jan 2029 |
| Alliance for Clinical Trials in Oncology | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 3 | Clear Cell Renal Cell Carcinoma | Nov 2037 |
| Avalyn Pharma | Nintedanib (AP02) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer … | Dec 2026 |
| Sun Yat-sen University | Anlotinib Hydrochloride Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET | VEGFR, PDGFRA, PDGFRB, FLT1, KIT | Phase 2 | Glioblastoma | Dec 2026 |
| Henan Cancer Hospital | Lenvatinib Mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Effectiveness | Dec 2026 |
| Chipscreen Biosciences | Ibcasertib Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor | AURKB, FLT1, FLT4, KDR | Phase 2 | Pancreatic Ductal Adenocarcinoma | Feb 2027 |
| City of Hope Medical Center | Lenvatinib Mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | Apr 2027 |
| Mannkind | Nintedanib (MNKD-201) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis | Dec 2027 |
| Criterium | Fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Colorectal Cancer; Metastatic Oesogastric Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma … | Dec 2027 |
| Hutchmed | Surufatinib Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | FGFR1, FLT1, FLT4, KDR | Phase 2 | Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma … | May 2028 |
| M.D. Anderson Cancer Center | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 2 | Renal Cell Carcinoma | Nov 2028 |
| University of Florida | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Bile Duct Cancer | Dec 2026 |
| AstraZeneca | cediranib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | KIT, PDGFRB, PDGFRA, FLT1, FLT4 | Phase 1 | Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer … | Dec 2026 |
| Betta Pharmaceuticals | X-82 Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 1 | DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib … | Jan 2027 |
| Sichuan University | Dual-targeting VEGFR1/PD-L1 CAR-T cells Bispecific CAR-T cells targeting VEGFR1 and PD-L1 | FLT1, CD274 | Phase 1 | Malignant Peritoneal Effusion | Jun 2027 |
| National Cancer Institute (NCI) | Tivozanib (AV-951) Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Cholangiocarcinoma | Dec 2028 |
Hepatocellular Carcinoma (12) Colorectal Cancer (11) Hepatocellular Carcinoma Non-resectable (7) Renal Cell Carcinoma (6) Intrahepatic Cholangiocarcinoma (6) Gastric Cancer (6) Metastatic Renal Cell Carcinoma (6) HCC (5) Clear Cell Renal Cell Carcinoma (5) Intrahepatic Cholangiocarcinoma (Icc) (5) Hepatocellular Carcinoma (HCC) (5) HCC - Hepatocellular Carcinoma (4)
small molecule (11), mixed (11), other (1), antibody (1)
Hutchmed (2) Merck & Co. (MSD) (1) University Hospital, Bordeaux (1) Takeda (1) AO GENERIUM (1) Chipscreen Biosciences (1) National Cancer Institute (NCI) (1) Adverum Biotechnologies (1) Avalyn Pharma (1) Alliance for Clinical Trials in Oncology (1) Shanghai Junshi Bioscience Co., Ltd. (1) University of Florida (1) Mannkind (1) Sun Yat-sen University (1) Sichuan University (1) Ocular Therapeutix (1) AstraZeneca (1) Jiangsu HengRui Medicine (1) City of Hope Medical Center (1) Henan Cancer Hospital (1)
FLT4 (20) KDR (19) PDGFRB (10) KIT (7) PDGFRA (6) CD274 (2) PDCD1 (1) AURKB (1) VEGFR (1) FLT3 (1) FGFR1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.